Limited time75% off all plans
Get the app

Prenatal diagnosis of congenital defects

Prenatal diagnosis of congenital defects

Prenatal diagnosis of congenital defects

On this page

Prenatal Screening - The First Look

  • First Trimester (11-13+6 wks): Combined test is standard.
    • Biochemical: ↑ free β-hCG, ↓ PAPP-A.
    • USG: ↑ Nuchal Translucency (NT).
  • Second Trimester (15-20 wks): Quadruple test.
    • Markers: ↓ AFP, ↑ β-hCG, ↓ uE3, ↑ Inhibin A.
  • NIPS/NIPT: Non-invasive prenatal screening/testing. Highest detection rate for aneuploidies.

⭐ In Down Syndrome, all markers in the second-trimester screen are down except for hCG and Inhibin A, which are high.

Fetal Nuchal Translucency (NT) Ultrasound Measurement

1st Trimester Screening - The Early Birds

  • When: 11-14 weeks gestation (or CRL 45-84 mm).
  • What: A combined screening test for aneuploidies (Trisomy 21, 18, 13).
  • Components:
    • Biochemical Markers (Double Marker Test):
      • ↓ PAPP-A (Pregnancy-Associated Plasma Protein-A)
      • ↑ Free β-hCG (human chorionic gonadotropin)
    • Sonographic Markers (NT Scan):
      • ↑ Nuchal Translucency (NT)
      • Absent/Hypoplastic Nasal Bone

Fetal Ultrasound: Nuchal Translucency Measurement

⭐ The combined test boasts a detection rate of ~85% for Down Syndrome. It is a screening test; positive results require diagnostic confirmation (e.g., CVS or amniocentesis).

2nd Trimester Screening - The Mid-Game Scan

  • Timing: 15-20 weeks (ideal: 16-18 weeks).
  • Tests: Ultrasound (for anomalies) + Maternal serum screening.
  • Quadruple Test: Measures 4 markers:
    • Alpha-fetoprotein (AFP)
    • Human chorionic gonadotropin (hCG)
    • Unconjugated estriol (uE3)
    • Inhibin A

Fetal ultrasound images for prenatal anomaly detection

⭐ The Quadruple test has a detection rate of approximately 80% for Down syndrome.

Invasive Diagnostic Tests - The Decisive Divers

  • Definitive diagnosis for chromosomal/genetic disorders. Involves sampling fetal tissue/fluid, each with specific timing and risks.
TestGestational Age (GA)Risk of Fetal LossKey Points
Chorionic Villus Sampling (CVS)10-13 wks~1%Earliest test. Cannot detect NTDs.
Amniocentesis15-20 wks~0.5%Can detect NTDs (↑AFP).
Cordocentesis (PUBS)>18 wks1-2%Rapid karyotype; fetal therapy.

NIPT & Beyond - The DNA Detective

  • Non-Invasive Prenatal Testing (NIPT): Analyzes cell-free fetal DNA (cffDNA) from maternal plasma.
    • Performed from 10 weeks gestation onwards.
    • Screens for common aneuploidies (Trisomy 21, 18, 13) & sex chromosome abnormalities.
    • High detection rate for Down syndrome (>99%).
  • Confirmatory Tests: NIPT is a screening tool; positive results require confirmation via Chorionic Villus Sampling (CVS) or Amniocentesis.

Fetal Fraction: The proportion of cffDNA in maternal blood. A level <4% is a major cause of NIPT failure or false-negative results.

High‑Yield Points - ⚡ Biggest Takeaways

  • Nuchal Translucency (NT) is the most important first-trimester ultrasound marker for Down syndrome.
  • The double marker test (PAPP-A, β-hCG) is the key first-trimester biochemical screen.
  • The quadruple screen (AFP, hCG, estriol, inhibin A) is the standard second-trimester biochemical test.
  • Amniocentesis (15-20 weeks) and Chorionic Villus Sampling (CVS) (10-13 weeks) are the primary invasive diagnostic tests.
  • Cell-free fetal DNA (cffDNA) is the most sensitive non-invasive screening test for aneuploidy.

Continue reading on Oncourse

Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.

CONTINUE READING — FREE

or get the app

Rezzy — Oncourse's AI Study Mate

Have doubts about this lesson?

Ask Rezzy, your AI Study Mate, to explain anything you didn't understand

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

START FOR FREE